Several of small-molecule STAT3 inhibitors, as well as other classes of agents, have been shown to be effective in targeting STAT3 and inhibiting tumor growth in preclinical models, including HNSCC, [33, 40]. This evidence concerns the gene STAT3 and head and neck squamous cell carcinoma.